Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Alvocidib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tolero Presents Biomarker Identification Strategies for Invg Agents Alvocidib
    Tolero Presents Biomarker Identification Strategies for Invg Agents Alvocidib

    22 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/tolero-pharmaceuticals-presents-biomarker-identification-strategies-for-investigational-agents-alvocidib-and-tp-1287-at-aacr-virtual-meeting-ii-2020-301080619.html

    PRNEWSWIRE
    22 Jun 2020
    Share Share
    Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study
    Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study

    12 Jun 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/tolero-pharmaceuticals-presents-findings-from-phase-1-zella-101-clinical-study-evaluating-investigational-agent-alvocidib-in-patients-with-newly-diagnosed-acute-myeloid-leukemia-at-virtual-eha-annual-congress-2020-301074874.html

    PRNEWSWIRE
    12 Jun 2020
    Share Share
    Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study
    Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study

    15 Jan 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tolero-pharmaceuticals-announces-first-patient-dosed-in-phase-2-zella-202-study-of-investigational-agent-alvocidib-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-following-treatment-with-venetoclax-and-hma-combinat-300987212.html

    PR NEWSWIRE
    15 Jan 2020
    Share Share
    AbbVie, Tolero team up to test Venclexta combo in AML
    AbbVie, Tolero team up to test Venclexta combo in AML

    17 Aug 2018

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/abbvie-tolero-team-up-to-test-venclexta-combo-aml

    Amirah Al Idrus FIERCE BIOTECH
    17 Aug 2018
    Share Share
    Tolero Pharmaceuticals Receives European Medicines Agency Orphan Drug Designation For Alvocidib For The Treatment Of Acute Myeloid Leukemia
    Tolero Pharmaceuticals Receives European Medicines Agency Orphan Drug Designation For Alvocidib For The Treatment Of Acute Myeloid Leukemia

    26 Feb 2015

    // BIOSPACE

    http://www.biospace.com/News/tolero-pharmaceuticals-receives-european-medicines/366271/source=MoreNews

    BIOSPACE
    26 Feb 2015
    Share Share